Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Genesis Biopharma have entered into a process development and scale-up agreement with Switzerland-based Lonza for the manufacturing of Contego.
Subscribe to our email newsletter
Genesis Biopharma’s Contego is an autologous cell therapy product indicated for the treatment for Stage IV metastatic melanoma.
Lonza Therapeutic Cell Solutions head David Smith said Lonza is pleased to be in partnership with Genesis Biopharma, and to bring expertise in large-scale autologous cell therapy production to the task of making Contego widely available to patients suffering from metastatic melanoma.
Lonza is a provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.